About Arch Venture Partners
Arch Venture Partners is a venture capital firm founded in 1986. It is primarily based out of Chicago, United States. As of Sep 2026, Arch Venture Partners is an active investor, having invested in 293 companies, with 10 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series F round of Encoded Overall, Arch Venture Partners portfolio has seen 2 unicorns, 47 IPOs and 79 acquisitions including key companies like Alnylam, Sana Biotechnology and Aledade. A lot of funds co-invest with Arch Venture Partners, with names like Google Ventures sharing a substantial percentage of its portfolio. Arch Venture Partners has team of 47 people including 11 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 8 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Arch Venture Partners' List of Top Investments
Arch Venture Partners has a portfolio of 293 companies, including 2 unicorns. Their most notable investments are in Tome Biosciences and OncoResponse.Their portfolio spans across United States, China, United Kingdom and 10 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 23 other sectors, across stages such as Series A, Series B and 8 more. Here is the list of top investments by Arch Venture Partners:1. Alnylam
Developer of RNA interference-based therapeutics for multiple disorders. Its pipeline includes drugs that are used to treat hereditary ATTR Amyloidosis, acute hepatic porphyria, and treating hypercholesterolemia. It also develops drugs for cardiometabolic diseases, infectious diseases, central nervous system, and ocular diseases.
Key facts about Alnylam
- Founded Year: 2002
- Location: Cambridge (United States)
- Annual Revenue: $1B+ as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $17M
- Employee Count: 2,984 as on Jul 31, 2026
- Investors: Colt Ventures, Atlas Venture and 13 Others
- Latest Funding Round: Post IPO, Aug 17, 2020, $*****
- Highlight: Public
Developer of engineered cell therapies for treating various human diseases. Research focuses on repairing or controlling genes within cells and replacing damaged or missing cells to address underlying disease causes. Drug candidates target conditions including diabetes, cancers, and autoimmune disorders. The work involves cellular biology and machine learning to create therapeutic interventions.
Key facts about Sana Biotechnology
- Founded Year: 2018
- Location: Seattle (United States)
- Stage: Public
- Total Funding till date: $821M
- Employee Count: 258 as on Jul 31, 2026
- Investors: HTIF, Baillie Gifford and 18 Others
- Latest Funding Round: Post IPO, Aug 10, 2026, $*****
- Highlight: Public
3. Aledade
Provider of primary care physician platform to deliver care for patients. The platform offers data analytics, guided workflows, healthcare policy expertise, and payer relationships for independent practices health centers, and clinics. It helps practioners and health centers optimize patient outcomes and generate revenue through value based care.
Key facts about Aledade
- Founded Year: 2014
- Location: Bethesda (United States)
- Valuation: $*****
- Stage: Series F
- Total Funding till date: $780M
- Employee Count: 1,936 as on Jul 31, 2026
- Investors: Meritech, Section Partners and 18 Others
- Latest Funding Round: Conventional Debt, Dec 02, 2025, $*****
- Highlight: Editors' Pick
Developer of therapies to treat neurodegenerative diseases. The company's product pipeline includes a small molecule inhibitor of RIP1 kinase to treat Alzheimer's and ALS by regulating inflammatory signaling and affecting glial dysfunction in the brain. Also, provides an LRRK2 inhibitor to treat Parkinson's disease.
Key facts about Denali Therapeutics
- Founded Year: 2015
- Location: San Francisco (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2023
- Stage: Public
- Total Funding till date: $347M
- Employee Count: 603 as on Jul 31, 2026
- Investors: Foresite Capital, Baillie Gifford and 10 Others
- Latest Funding Round: Post IPO, Feb 27, 2024, $*****
- Highlight: Public
5. Aira
Provider of remote assistance solution for blinds and the visually impaired. It provides smart glasses app that enables users to connect with a network certified agents along with family and friends. The agents use a real-time interactive cloud-based dashboard built to provide an augmented reality context for remote users by the processing of live data streams from cameras, GPS, and other sensor systems from wearable platforms.
Key facts about Aira
- Founded Year: 2014
- Location: Carlsbad (United States)
- Stage: Acquired
- Total Funding till date: $192M
- Employee Count: 172 as on Jul 31, 2026
- Investors: Deep Learning, Felicis Ventures and 10 Others
- Latest Funding Round: Series B, Jan 16, 2024, $*****
- Highlight: Acquired
Arch Venture Partners' Year-on-Year Investment Trends
Arch Venture Partners has invested in 294 companies over the last 37 years, with an average of 13 new investments annually in the last 10 years. In 2025, it made 19 investments, while as of Sep 2026, it has made 17 investments in this year. Its most recent first time investment was in Oratomic and most recent follow-on round was in Encoded.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 5 | 12 | 17 |
2025 | 9 | 10 | 19 |
2024 | 11 | 14 | 25 |
2023 | 17 | 13 | 30 |
2022 | 17 | 12 | 29 |
2021 | 15 | 18 | 33 |
2020 | 14 | 12 | 26 |
2019 | 16 | 12 | 28 |
2018 | 14 | 11 | 25 |
2017 | 12 | 13 | 25 |
Arch Venture Partners' Investments by Stage
Arch Venture Partners is primarily an Early Stage Investor investor majorly investing in Series A (130) rounds where average round size is $7.84B, Series B (54) rounds where average round size is $4.52B and Seed (16) rounds where average round size is $495M.Stage of entry | No. of Investments |
|---|---|
Series A | 130 |
Series B | 54 |
Seed | 16 |
Series C | 15 |
Series D | 11 |
Others | 10 |
Note: We have considered here, only first round of investments
Arch Venture Partners' Investments by Sector
Arch Venture Partners has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Sustainability Tech. Notably, it has invested in 254 Tech companies, 235 Enterprise (B2B) companies, 64 Software companies and at least 32 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 173 |
High Tech | 70 |
Enterprise Applications | 28 |
HealthTech | 25 |
Sustainability Tech | 20 |
Others | 98 |
Note: We have considered here, only first round of investments
Arch Venture Partners' Investments by Geography
Arch Venture Partners has made most investments in United States (212), followed by China where it has made 10 investments.Country | No. of Investments |
|---|---|
United States | 212 |
China | 10 |
United Kingdom | 4 |
Germany | 2 |
Sweden | 2 |
Others | 4 |
Note: We have considered here, only first round of investments
Arch Venture Partners' recent investments
Arch Venture Partners has made 17 investments in 2026 so far. Encoded and Moonwalk are the latest among them.Here are the most recent investments by Arch Venture Partners:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 09, 2026 | United States | Series F | 3095 | [+10] | |
Sep 08, 2026 | United States | Series B | 5626 | [+5] | |
Aug 22, 2026 | United States | Series A | 5463 | ||
Aug 18, 2026 | United States | Series A | 2474 | ||
Aug 06, 2026 | United States | Series E | 7319 |
Unicorns in Arch Venture Partners' Portfolio
Arch Venture Partners has 2 unicorns in its portfolio - Xaira and Aledade. The most recent unicorn in their portfolio is Xaira. It became a unicorn in 2024.Here is a list of unicorns in Arch Venture Partners' portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
63 | AI-enabled platform for drug discovery and development | 2023 | San Francisco | Series D | wchrggn | ||
72 | Provider of primary care physician platform to deliver care for patients | 2014 | Bethesda | Series F | m{ernvb |
IPOs and Publicly Listed companies in Arch Venture Partners' Portfolio
47 of Arch Venture Partners' portfolio companies have become public. Kardigan got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jun 2026 at marketcap of $1.43B and Parabilis Medicines got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $2.33B.Here are Arch Venture Partners' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 18, 2026 | Jan 13, 2025 | Series A | 9020 | |
Jun 10, 2026 | Nov 17, 2022 | Series D | 5297 | |
May 01, 2026 | Apr 09, 2024 | Series A | 8743 | |
Feb 27, 2026 | Nov 18, 2021 | Series B | 9332 | |
Jan 31, 2025 | Mar 01, 2019 | Series C | 3645 |
Acquired companies in Arch Venture Partners' Portfolio
79 companies from Arch Venture Partners' portfolio have been acquired. The most recent acquisition was Homeward in Aug 2026 by Cityblock for $*****.Here are Arch Venture Partners' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 20, 2026 | Aug 03, 2022 | Series B | 1863 | |
Feb 10, 2026 | Sep 28, 2022 | Seed | 7833 | |
Jan 12, 2026 | Apr 27, 2020 | Series A | 6559 | |
Jan 07, 2026 | Aug 15, 2024 | Series B | 9337 | |
Dec 29, 2025 | Feb 28, 2000 | Series A | 6830 |
_1588141906819.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Team profile of Arch Venture Partners
Arch Venture Partners has a team of 47 members including 11 Partners, 17 Venture Partners and 6 Principals located in United States, Japan and 2 more locations. Arch Venture Partners' team sits on the board of 2 companies.Here is a list of top team members in Arch Venture Partners:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | United States | - | ||
Partner | Seattle | - | ||
Partner | London | - | ||
Partner | Chicago | |||
Partner | Chicago | - | ||
Partner | San Francisco | - | ||
Partner | Chicago | - | ||
Partner | Henderson | - | ||
Partner | Seattle | - | ||
Partner | Redwood City | - |
Co-investors of Arch Venture Partners
Over the past 37 years, 1193 investors have co-invested in Arch Venture Partners's portfolio companies. This includes funds and angels.
- Invested before Arch Venture Partners: HHS, Accelerator Life Science Partners and 176 others have invested in rounds before Arch Venture Partners. There are 8 companies where HHS has invested before Arch Venture Partners and 3 companies where Accelerator Life Science Partners has invested before Arch Venture Partners.
- Top Co-investors of Arch Venture Partners: 477 investors entered a company along with Arch Venture Partners. These include investors like Google Ventures (29 companies).
- Invested after Arch Venture Partners: A total of 538 investors have invested in Arch Venture Partners's portfolio after their investments. Top Investors include Fidelity Investments (19 companies), Invus (14 companies) and Alexandria (14 companies).
Recent News related to Arch Venture Partners
•
•
Astromech Secures $20M for Biological Operating System DevelopmentSiliconAngle•Aug 21, 2026•astromech, Arch Venture Partners
•
•
Arch, Khosla lead quantum startup Oratomic’s $300m series ATech in Asia•Jul 11, 2026•Khosla Ventures, Arch Venture Partners, Lowercarbon, Bezos Expeditions and 5 others
•
Jeff Bezos' Family Office Accelerates AI Bets with Multiple Startup InvestmentsPYMNTS.com•Jul 02, 2026•CuspAI, Bezos Expeditions, Khosla Ventures, Arch Venture Partners and 1 other
•
•
•
•
SonoThera raises $125M for non-viral gene therapy approachEndpoints•Jun 10, 2026•SonoThera, Medical Excellence Capital, UCB Ventures, Leaps by Bayer and 10 others
•
City Therapeutics Secures $99.5M Series B for RNAiVentureburn•Jun 09, 2026•City Therapeutics, NYBC Ventures, Regeneron Ventures, Rock Springs Capital and 6 others
